Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)
Paris, November 23, 2021 – PKvitality, a French company specialized in Health and Sport bio-wearables today announced the start of a clinical study to determine the accuracy of the K’Watch Glucose. The trial is conducted with the AMCR Institute Inc, a clinical research center focused on diabetes and obesity with worldwide renown medical device expertise in the metabolic area. Based on a unique SkinTaste technology, the K’Watch Glucose will be the first wearable smartwatch medical device that measures and displays glucose level continuously, effortlessly, and painlessly. This major milestone is partly financed thanks to grant and equity investment from the European Commission through the EIC (European Innovation Council) fund.
PKvitality has been chosen by the EIC as one of the top innovative companies to offer a unique solution to a major global issue: today, the diabetes population is estimated to be of 463M people and should rise to 700M by 2045. The K’Watch Glucose project aims to facilitate the lives of millions of diabetes patients by offering a painless and discreet continuous glucose monitor.
PKvitality’s mission is to enable everyone to contribute actively to their well-being and health through products that are simple and comfortable to use. Thus, its K’Watch Glucose smartwatch will be the world’s first CGM device that will track glucose levels discreetly and continuously at the wrist.
French medtech companies are tackling diabetes and innovating, as proven by the sheer number of patents filed in 2021. Each year, the National Industrial Property Institute (INPI)ranks the top patent filers, highlighting companies that invest in innovation.
Paris, May 16, 2022 – PKvitality, a French company specializing in Bio-wearable Health and Sports, has been selected to join the 1st promotion of Future4care, the largest eHealth accelerator in Europe.
PARIS–(BUSINESS WIRE)–Cibiltech announced today that the first patient has been enrolled in the CIBIL clinical trial “Clinical Impact of the iBox as an early Intervention tool”. A prospective randomized controlled trial to assess the use of a software predicting allograft survival in the follow-up of kidney transplanted patients (NCT05112315). This marks the beginning of this first-of-its-kind clinical trial conducted in Europe evaluating a digital health solution.